Harris aims to broaden some IRA provisions, including Medicare’s power to negotiate drug prices, while Trump has publicly endorsed a more industry-friendly approach.

Data Validation and Compliance: The Sapio LIMS and ELN ensure adherence to the FDA and EMA-guided IGX assay validation approach, providing for monitoring and reporting on cut points, sensitivity, ...

Alimentiv, a full-service GI CRO and pioneer in IBD medical imaging solutions since 1986, is excited to announce the expansion of its partnership with Satisfai Health, a leader in AI medical solutions ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.

To enhance patient outcomes and increased trial success, Convert Pharma is leveraging companion AI- and genetic biomarkers, a ...

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

In a breakthrough for cancer research, Medgnosis has leveraged its state-of-the-art generative AI (GenAI) system to transform drug discovery. This GenAI targets both druggable and undruggable proteins ...

The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.